Barclays PLC Raises Holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Barclays PLC lifted its holdings in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 126.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 277,565 shares of the biopharmaceutical company’s stock after purchasing an additional 154,854 shares during the quarter. Barclays PLC owned 0.17% of ACADIA Pharmaceuticals worth $4,269,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Marshall Wace LLP raised its position in ACADIA Pharmaceuticals by 431.1% in the 2nd quarter. Marshall Wace LLP now owns 2,774,353 shares of the biopharmaceutical company’s stock worth $45,083,000 after buying an additional 2,251,940 shares during the last quarter. Millennium Management LLC raised its holdings in shares of ACADIA Pharmaceuticals by 36.2% during the second quarter. Millennium Management LLC now owns 2,937,714 shares of the biopharmaceutical company’s stock valued at $47,738,000 after purchasing an additional 781,070 shares during the last quarter. Iron Triangle Partners LP bought a new position in ACADIA Pharmaceuticals during the third quarter valued at approximately $11,535,000. Dimensional Fund Advisors LP purchased a new stake in ACADIA Pharmaceuticals in the second quarter worth approximately $10,550,000. Finally, Eventide Asset Management LLC purchased a new stake in ACADIA Pharmaceuticals during the 3rd quarter valued at $8,882,000. 96.71% of the stock is owned by institutional investors.

ACADIA Pharmaceuticals Stock Up 0.8 %

Shares of NASDAQ:ACAD opened at $16.87 on Friday. ACADIA Pharmaceuticals Inc. has a 52-week low of $14.15 and a 52-week high of $32.59. The stock has a market cap of $2.81 billion, a P/E ratio of 21.63 and a beta of 0.40. The business has a fifty day moving average of $16.24 and a two-hundred day moving average of $16.22.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The business had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $248.83 million. During the same period last year, the business earned ($0.40) earnings per share. The business’s revenue for the quarter was up 18.3% on a year-over-year basis. On average, equities analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.73 earnings per share for the current year.

Insider Buying and Selling

In related news, CFO Mark C. Schneyer sold 10,259 shares of the firm’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total value of $172,453.79. Following the completion of the sale, the chief financial officer now owns 53,302 shares in the company, valued at $896,006.62. This trade represents a 16.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider James Kihara sold 4,073 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $16.81, for a total transaction of $68,467.13. Following the transaction, the insider now directly owns 19,863 shares in the company, valued at approximately $333,897.03. This trade represents a 17.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,661 shares of company stock worth $414,551 over the last 90 days. 28.30% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ACAD has been the subject of several research analyst reports. Raymond James reaffirmed a “market perform” rating on shares of ACADIA Pharmaceuticals in a report on Thursday, October 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price target on shares of ACADIA Pharmaceuticals in a research report on Thursday, November 7th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, November 7th. Finally, StockNews.com lowered shares of ACADIA Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 14th. Six analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. According to MarketBeat, ACADIA Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $25.60.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.